Melanie De Almeida, Author at Labiotech.eu

About

Former journalist intern. Melanie has studied in Germany and Denmark and did an internship at Novo Nordisk, where she had a glimpse to the workings of pharma. She is now a Ph.D. student at the IMP in Vienna.

Articles by Melanie De Almeida

News and Trends 30 Nov 2018

Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies

Update (30/11/2018): IGEM Therapeutics has increased the total raised in Series A to £5M (€5.6M) with the participation of two new investors, Alsa Holdings and UCL Technology Fund. The funding will go towards the development of a new generation of antibody drugs for cancer. Published on 20/06/2017 IGEM Therapeutics has raised £2M (€2.3M) in Series A […]

November 30, 2018 - 2 minutesmins - By Melanie De Almeida

In Depth 14 Nov 2018

Taking Biotech to the Next Level with Laboratory Automation

Automation is slowly taking over our lives, ranging from smart homes to self-driving cars. With experiments becoming ever more complex and datasets more immense, a question that comes to mind: can we automate biotech research? Most pharma and biotech companies, and in part also academic labs, have automated sections of their processes and make use […]

November 14, 2018 - 6 minutesmins - By Melanie De Almeida

News and Trends 13 Mar 2018

French Biotech Takes its Oral Diabetes Drug to Phase III

Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks to a mechanism of action that targets the pancreas, the liver and muscles simultaneously. The new trials will confirm whether these effects are maintained in a larger […]

March 13, 2018 - 3 minutesmins - By Melanie De Almeida

In Depth 6 Feb 2018

CRISPR/Cas9: Could the Gene Editing Technology be the Future of Drug Discovery?

The emergence of CRISPR/Cas9 technologies has enabled almost unlimited gene editing opportunities. Not only could it be used as a therapeutic tool, the genome editing tool could kickstart a revolution in drug discovery. To date, much of the attention on CRISPR/Cas9, which stands for clustered regularly interspaced short palindromic repeats, has revolved around its potential as […]

February 6, 2018 - 9 minutesmins - By Melanie De Almeida

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […]

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 26 Jul 2017

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018. Published on 27/06/2017 Verona Pharma has secured regulatory approval in five European countries to run a Phase IIb trial with its dual PDE3/4 inhibitor in […]

July 26, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 20 Jul 2017

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […]

July 20, 2017 - 3 minutesmins - By Melanie De Almeida

In Depth 11 Jul 2017

Regenerating the Body With Stem Cells – Hype or Hope?

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding. “The overall stem cell therapy field has failed today to show […]

July 11, 2017 - 9 minutesmins - By Melanie De Almeida

Startup Scout 30 Jun 2017

This Danish Biotech Thinks it Can Tackle the Obesity Epidemic

Apart from boasting big players in the space of metabolic diseases including Novo Nordisk and Zealand Pharma, Copenhagen is a hotspot for research on obesity and diabetes. This week we had a look at Copenhagen’s latest addition to the field, Antag Therapeutics. Mission: Antag Therapeutics is working on new treatments for the growing number of patients with obesity. […]

June 30, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 29 Jun 2017

New Drug for Neuropathic Pain Is Forging its Way through the Clinic

Pharmaleads has scored positive results in a first Phase I trial for its DENKI peptide PL265 to treat chronic neuropathic pain. The treatment of neuropathic pain commonly involves the prescription of opioids, anti-depressants or anti-convulsants, despite limited efficacy and marked side-effects of these drugs. Paris-based Pharmaleads is exploring new pathways to treat pain based on so-called DENKI peptides […]

June 29, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 28 Jun 2017

Video: The Next Big Thing in Biotech according to Sofinnova’s Antoine Papiernik

Antoine Papiernik, Managing Partner at the famous European biotech VC Sofinnova, closed Refresh this year with a keynote on the next big thing in biotech. Papiernik has more than 20 years of experience as a VC investor and has helped build major European biotechs like Actelion, ProQR or Movetis. Being part of the leading edge […]

June 28, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 27 Jun 2017

Green Biotech Enters Partnership to Advance the Infinite Recycling of Plastics

Carbios has teamed up with TechnipFMC in order to move Carbios’ enzymatic recycling process for PET plastics from the laboratory to the pilot scale. French Carbios is looking to combat the limits of current thermo-mechanical recycling processes using an enzyme-based degradation process that paves the way to infinite recycling of PET. The annual production of PET, one […]

June 27, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us